Michel Bouvier

Michel Bouvier (born September 14, 1958) is a Canadian biochemist and molecular pharmacologist. He is a professor of biochemistry and molecular medicine at Université de Montréal; a principal investigator and the Chief Executive Officer at the Institute for Research in Immunology and Cancer; and an Associate Vice-President in Research, Scientific Discovery, Creation and Innovation at Université de Montréal. His work focuses on the study of cell signaling towards the discovery of new pharmaceutical drugs.[3]

Michel Bouvier
Born (1958-09-14) September 14, 1958
CitizenshipCanadian
AwardsFellow of the Academy of Science of the Royal Society of Canada[1]/ Fellow of the Canadian Academy of Health Sciences / Canada Research Chair in Signal Transduction and Molecular Pharmacology[2]
Scientific career
FieldsBiochemistry and molecular pharmacology

Biography

Michel Bouvier earned a B.Sc. in Biochemistry (1979) and a Ph.D. in Neurological Sciences (1985) from Université de Montréal, and then completed a post-doctoral fellow (1985-1989) at Duke University under the supervision of Dr. Robert J. Lefkowitz (2012 Nobel Prize in Chemistry[4]). Bouvier is a professor in the Department of Biochemistry and Molecular Medicine at the Faculty of Medicine of Université de Montréal and a principal investigator at the Institute for Research in Immunology and Cancer (IRIC) at Université de Montréal.[5]

Research

He is a world-known expert[6][7] in cell signaling and drug discovery, notably in the field of G protein-coupled receptors (GPCRs).[8] GPCRs constitute the largest single protein family involved in the transduction of hormonal signals and neurotransmitters. Their physiological significance makes them a prime target in drug development, and over a third of existing drugs use GPCRs as their target site of action. Bouvier’s work in the regulation of receptors led to new paradigms (inverse agonism; pharmacological chaperones; receptor polymerization; and pluri-dimensionality of signaling), which, coupled with the development of bioluminescence resonance energy transfer (BRET)-based methods, have a direct impact on drug discovery.[9] He has authored over 260 scientific articles,[10] filed 36 patent applications, and delivered over 400 lectures as a guest lecturer. Bouvier holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology[11]

gollark: Oh, you can use a docstring for that? I never actually checked.
gollark: Huh?
gollark: Loops are !!IMPERATIVE!!, map is glorious functional purity.
gollark: No, small. Anyway, the weird format string/lambda/map oneliner is much clearer than a loop.
gollark: No use using two lines when one works, my monitor isn't that small.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.